OliX PharmaceuticalsInc Cash Flow Conversion Efficiency
OliX PharmaceuticalsInc cash flow conversion efficiency. Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has a cash flow conversion efficiency ratio of -0.065x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-15.43 Billion ≈ $-10.46 Million USD) by net assets (₩237.42 Billion ≈ $160.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OliX PharmaceuticalsInc (2016–2025)
Cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2025. This chart illustrates how OliX PharmaceuticalsInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for OliX PharmaceuticalsInc for real-time trading data and today's change.
OliX PharmaceuticalsInc Cash Flow Conversion Ratio Explained
OliX PharmaceuticalsInc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OliX PharmaceuticalsInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OliX PharmaceuticalsInc ranked by their cash flow conversion efficiency. Also see OliX PharmaceuticalsInc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Fertilizer Co Ltd
TW:1722
|
0.001x |
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
0.040x |
|
Vanchip (Tianjin) Technology Co. Ltd. A
SHG:688153
|
N/A |
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
0.025x |
|
ROMANDE ENERGIE SA
SW:REHN
|
0.072x |
|
Hong Leong Industries Bhd
KLSE:3301
|
0.056x |
|
REX American Resources Corporation
NYSE:REX
|
-0.003x |
|
Henan Zhongyuan Expressway Co Ltd
SHG:600020
|
0.063x |
Annual Cash Flow Conversion Efficiency for OliX PharmaceuticalsInc (2016–2025)
The table below shows the annual cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2025. Review 226950 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩150.08 Billion ≈ $101.71 Million |
₩-15.90 Billion ≈ $-10.78 Million |
-0.106x | +93.26% |
| 2024-12-31 | ₩17.85 Billion ≈ $12.10 Million |
₩-28.04 Billion ≈ $-19.01 Million |
-1.571x | -273.62% |
| 2023-12-31 | ₩50.34 Billion ≈ $34.11 Million |
₩-21.17 Billion ≈ $-14.35 Million |
-0.421x | +9.67% |
| 2022-12-31 | ₩65.91 Billion ≈ $44.66 Million |
₩-30.68 Billion ≈ $-20.79 Million |
-0.466x | +54.75% |
| 2021-12-31 | ₩18.52 Billion ≈ $12.55 Million |
₩-19.05 Billion ≈ $-12.91 Million |
-1.029x | -1139.29% |
| 2020-12-31 | ₩45.29 Billion ≈ $30.69 Million |
₩-3.76 Billion ≈ $-2.55 Million |
-0.083x | +67.67% |
| 2019-12-31 | ₩41.80 Billion ≈ $28.33 Million |
₩-10.73 Billion ≈ $-7.27 Million |
-0.257x | -68.76% |
| 2018-12-31 | ₩54.94 Billion ≈ $37.23 Million |
₩-8.36 Billion ≈ $-5.67 Million |
-0.152x | +40.64% |
| 2017-12-31 | ₩18.68 Billion ≈ $12.66 Million |
₩-4.79 Billion ≈ $-3.24 Million |
-0.256x | +6.67% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
₩-3.45 Billion ≈ $-2.34 Million |
-0.275x | -- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more